会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 17. 发明授权
    • Motlin-like polypeptide and use thereof
    • Motlin样多肽及其用途
    • US5432261A
    • 1995-07-11
    • US943992
    • 1992-09-11
    • Masayasu KuronoTakahiko MitaniHaruo TakahashiKenichi TanakaKatsuya FujimuraYuji HayashiYohei KobayashiKiichi Sawai
    • Masayasu KuronoTakahiko MitaniHaruo TakahashiKenichi TanakaKatsuya FujimuraYuji HayashiYohei KobayashiKiichi Sawai
    • A61K38/00C07K14/63C12N15/16C07K14/00
    • C07K14/63A61K38/00C07K2319/02
    • A pharmaceutical composition for stimulating peristaltic contraction in the intestinal canal which contains a pharmaceutically acceptable carrier or excipient and an effective amount of a polypeptide, or a salt thereof, having a pharmacological activity similar to motilin. The polypeptide has the formula B.sub.1 -Z.sub.1 -A.sub.1 -Z.sub.2 -B.sub.2 -Thr-B.sub.3 -A.sub.2 -Glu-Z.sub.3 -C-Arg-X'-Gln-Glu-Lys-Glu-Arg-D-Lys-Gly-E-Y, with Z.sub.1,Z.sub.2 and Z.sub.3 each being an amino acid residue having a hydrophobic side-chain, A.sub.1 and A.sub.2 each being an amino acid residue such as Pro, Gly, Asn and Ser, B.sub.1, B.sub.2 and B.sub.3 are each an amino acid residue having a side-chain with an aromatic ring, C is Gln, Glu or Asp, D is Asn, Glu or Asp, X' is an amino acid residue other than Met, E is Gln, Lys or Arg, and Y is homoserine, homoserine-lactone or a peptide chain having amino acid residues not exceeding 10 and containing homoserine or homoserine-lactone at the C-terminal where the first amino acid of said peptide chain is other than Lys, Arg or Pro.
    • 一种用于刺激肠道蠕动收缩的药物组合物,其含有药学上可接受的载体或赋形剂和有效量的具有与胃动素相似的药理活性的多肽或其盐。 该多肽具有式B1-Z1-A1-Z2-B2-Thr-B3-A2-Glu-Z3-C-Arg-X'-Gln-Glu-Lys-Glu-Arg-D-Lys-Gly-EY, Z 1,Z 2和Z 3各自为具有疏水侧链的氨基酸残基,A1和A2各自为氨基酸残基,例如Pro,Gly,Asn和Ser,B1,B2和B3各自为具有 具有芳环的侧链,C是Gln,Glu或Asp,D是Asn,Glu或Asp,X'是Met以外的氨基酸残基,E是Gln,Lys或Arg,Y是高丝氨酸,高丝氨酸 β-内酯或氨基酸残基不超过10的肽链,并且在所述肽链的第一个氨基酸不是Lys,Arg或Pro的C末端含有高丝氨酸或高丝氨酸 - 内酯。
    • 19. 发明授权
    • Method of predicting threatened premature delivery in a pregnant woman
    • 孕妇威胁性早产的预测方法
    • US5290679A
    • 1994-03-01
    • US898681
    • 1992-06-15
    • Toshihiko TeraoNaohiro KanayamaAkihiro MoriokaYoshika YasudaMasami KamiyaJuichi AwayaMasayasu KuronoKiichi Sawai
    • Toshihiko TeraoNaohiro KanayamaAkihiro MoriokaYoshika YasudaMasami KamiyaJuichi AwayaMasayasu KuronoKiichi Sawai
    • A61K49/00G01N33/573C12Q1/00C12Q1/37
    • G01N33/573
    • Even when the specimen contains human granulocyte elastase in the form of a mixture of free elastase with an elastase-inhibitor complex or complexes, the present invention enables the total quantity of elastase in that specimen to be precisely detected. The inhibitor is added to free elastase to convert it into an elastase-inhibitor complex, whereby the quantity of elastase can be measured by immunoassay as the total amount including the previously existing elastase-inhibitor complex. It is possible to precisely measure the total amount of elastase in mucus collected from the cervical canal of a pregnant woman, sputum or a rinsed solution of bronchovesicular lavage in which free elastase is mixed with an elastase-inhibitor complex. It is thus possible to predict and prevent threatened premature delivery, premature delivery or premature rupture of membranes by immunoassay of mucus collected from the cervical canal of a pregnant woman, to make a diagnosis of chronic or repetitive airway infections and pulmonary emphysema based on chronic respiratory diseases by immunoassay of sputum and a rinsed solution of bronchovesicular lavage and to make a diagnosis of urinary tract infections by immunoassay of urine.
    • 即使样品含有游离弹性蛋白酶与弹性蛋白酶抑制剂复合物或复合物的混合物形式的人粒细胞弹性蛋白酶,本发明能够精确地检测该样本中弹性蛋白酶的总量。 将抑制剂加入到游离弹性蛋白酶中以将其转化成弹性蛋白酶抑制剂复合物,由此弹性蛋白酶的量可以通过免疫测定来测量,包括先前存在的弹性蛋白酶抑制剂复合物的总量。 可以精确测量从孕妇,痰液或冲洗的支气管泡灌洗液的宫颈管中收集的弹性蛋白酶的总量,其中游离弹性蛋白酶与弹性蛋白酶抑制剂复合物混合。 因此,可以通过从孕妇的宫颈管收集的粘液的免疫测定来预测和预防受威胁的早产,早产或过早破裂,以诊断慢性或重复性气道感染和基于慢性呼吸的肺气肿 通过免疫测定痰液的疾病和支气管泡灌洗液的清洗溶液,并通过免疫测定尿液来诊断尿路感染。